Drug stock price global investors see currency-adjusted

Global investors see currency-adjusted gains as an attractive hedge against U.S. market volatility. Patients with prescriptions will be able to access these drugs through a direct purchasing platform. Analysts and investors alike will be keeping a close eye on the performance of AbbVie in its upcoming earnings disclosure. The company is predicted to post an EPS of $3.26, indicating a 8.67% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $15.54 billion, indicating a 7.5% increase compared to the same quarter of the previous year. Recent data indicates the average drug stock price in the biotech sector has gained 2.3% over the past five trading sessions. Investors are closely watching Gilead Sciences (GILD), trading at $73.15, as pipeline updates for antivirals could trigger short-term rallies amid broader healthcare index strength.